03.06.2024  11:21:30 Zm. -0,800 Wolumen Bid11:21:30 Ask11:21:30 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
21,600EUR -3,57% -
Obrót: -
21,600Wolumen Bid: - 21,800Wolumen Ask: - 273,6 mlnEUR 1,97% 25,62

Opis działalności

PharmaSGP is a pure-play consumer health company with a broad portfolio of leading chemical-free non-prescription pharmaceuticals sold over the counter (“OTC”) and other healthcare products. PharmaSGP’s products are sold exclusively through pharmacies. Its products are based on natural active pharmaceutical ingredients with documented efficacy and fewer known side effects than most chemical-based pharmaceuticals. The Company’s core brands cover chronic indications, including pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RUBAXX® for rheumatic pain and RESTAXIL® for neuralgic pain. Furthermore, PharmaSGP has introduced leading products against sexual weakness and vertigo symptoms.
 

Zarząd & Rada nadzorcza

CEO
Natalie Weigand
Zarząd
Michael Rudolf
Rada nadzorcza
Dr. Clemens Fischer, Madlena Hohlefelder, Dr. Axel Rebien
 

Dane firmy

Nazwa: PharmaSGP Holding SE
Adres: Lochhamer Schlag 21,D-82166 Gräfelfing
Telefon: +49-611-2058-5528
Fax: +49-611-2058-5566
E-mail: info@pharmasgp.com
Internet: https://pharmasgp.com/
Przemysł: Służba zdrowia
Sektor: Przemysł Farmaceutyczny
Podsektor: Przemysł Farmaceutyczny
Koniec roku finansowego: 31.12
Free float: -
Data IPO: 19.06.2020

Relacje inwestorskie

Nazwa: Claudius Krause
Telefon: +49-611-2058-5535
Fax: -
E-mail: ir@pharmasgp.com

Główni akcjonariusze

FUTRUE GmbH / MVH Beteiligungs- und Beratungs-GmbH
 
77,82%
Freefloat
 
14,83%
Union Investment Privatfonds GmbH
 
4,70%
Swedbank Robur Fonder AB
 
2,65%